Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Plastic Surgery (Oakville, Ont.)|January 29, 2025
Exploring Skin Tone Diversity in a Plastic Surgery Resident Education CurriculumJane Zhu, Raahulan Rathagirishnan, Chantal Valiquette, et al.
American Journal of Respiratory and Critical Care Medicine|February 6, 2003
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosisDaphne Yee, Chantal Valiquette, Marthe Pelletier, et al.
BMC Public Health|January 22, 2021
Effects of programmatic interventions to improve the management of latent tuberculosis: a follow up study up to five months after implementationMercedes Yanes-Lane, Anete Trajman, Mayara Lisboa Bastos, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 26, 2024
Long-Term Protective Effect of Tuberculosis Preventive Therapy in a Medium/High Tuberculosis Incidence SettingLeidy Anne Alves Teixeira, Braulio Santos, Marcelo Goulart Correia, et al.
BMC Infectious Diseases|May 20, 2020
Solutions to improve the latent tuberculosis Cascade of Care in Ghana: a longitudinal impact assessmentLeila Barss, Joseph Obeng, Federica Fregonese, et al.
The Lancet. Infectious Diseases|December 24, 2019
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trialsJonathon R Campbell, Anete Trajman, Victoria J Cook, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|September 11, 2025
A necessary paradigm shift: recognizing the surgeon-advocate in academic surgeryAdom Bondzi-Simpson, Betel Yibrehu, Amanpreet K Brar, et al.
Plos One|April 18, 2019
The mTST - An mHealth approach for training and quality assurance of tuberculin skin test administration and readingSaeedeh Moayedi-Nia, Leila Barss, Olivia Oxlade, et al.
The Journal of Infectious Diseases|January 27, 2026
Population pharmacokinetic modeling of standard- and high-dose rifampicin for tuberculosis preventive therapy in the 2R2 randomized controlled trialFajri Gafar, Elin M Svensson, Vycke Yunivita, et al.
Pageof 2